USPTO Grants Trademark Registration for LATITUDE Pharmaceuticals for ClearSol® Solubilization Platform

SAN DIEGO, CALIFORNIA, November 16, 2023 – LATITUDE Pharmaceuticals Inc. ("LATITUDE"), a CDMO providing innovation drug formulations, drug delivery technologies, and GMP manufacture for the biopharmaceutical industry, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark ClearSol®. This trademark is granted under registration number 7,218,997 in relation to "Chemicals in the nature of solubilizers for use in the manufacture of pharmaceutical products and for research purposes; … for use in pharmaceutical products to improve stability, bioavailability and dosing of pharmaceutical ingredients".

This trademark registration represents a significant milestone for LATITUDE as it adds to the company's reputation as a leading biopharmaceutical CDMO providing innovative drug formulations and drug delivery technologies for its clients. ClearSol® represents the company's ability to develop novel, safe yet highly effective solutions for the solubilization of pharmaceutical actives for the development of novel human therapeutics.

ClearSol® is an aqueous solubilization vehicle that combines three key GRAS and FDA-approved injectable excipients in a proprietary composition to provide extraordinary drug-solubilization activity. The vehicle's safety has been established in numerous animal studies and in a US Phase 1 human clinical trial. To date, ClearSol™ has solubilized about 80% of tested highly insoluble drugs to adequate concentrations for their dosing by injection, which is superior to the performance of other solubilization technologies on the market.

About LATITUDE:
A small and highly customer-responsive CDMO, LATITUDE is a recognized leader in the development of innovative drug formulations and drug delivery systems for the biopharmaceutical industry. The company is highly regarded for its intellectual property portfolio and innovative approaches to developing pharmaceutical formulations for

problematic and/or highly insoluble drug molecules. LATITUDE also provides GMP manufacturing of pharmaceutical formulations for Phase 1 and Phase 2 clinical trials.